argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-29 07:42 |
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Bus…
|
English | 133.5 KB | ||
| 2024-02-26 07:35 |
argenx to Present at Upcoming Investor Conferences
|
English | 21.5 KB | ||
| 2024-02-22 07:31 |
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business U…
|
English | 17.5 KB | ||
| 2024-02-20 07:35 |
argenx Announces FDA Acceptance of Supplemental Biologics License Application w…
|
English | 63.8 KB | ||
| 2024-01-18 07:35 |
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc…
|
English | 36.1 KB | ||
| 2024-01-08 07:37 |
argenx Highlights 2024 Strategic Priorities
|
English | 87.1 KB | ||
| 2024-01-02 07:49 |
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
English | 18.7 KB | ||
| 2023-12-20 09:14 |
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphig…
|
English | 21.2 KB | ||
| 2023-12-08 16:54 | English | 580.8 KB | |||
| 2023-11-28 07:34 |
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Prim…
|
English | 115.3 KB | ||
| 2023-11-16 15:15 |
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgart…
|
English | 45.6 KB | ||
| 2023-11-01 08:18 |
argenx to Present at Upcoming Investor Conferences
|
English | 21.7 KB | ||
| 2023-11-01 08:16 |
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease a…
|
English | 206.5 KB | ||
| 2023-10-31 08:01 |
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
|
English | 129.6 KB | ||
| 2023-10-24 07:34 |
argenx to Report Third Quarter 2023 Financial Results and Business Update on Oc…
|
English | 21.3 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
